Status:
COMPLETED
Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation After Liver Transplantation
Lead Sponsor:
University of Roma La Sapienza
Conditions:
Sarcopenia
Eligibility:
MALE
18-70 years
Phase:
NA
Brief Summary
Sarcopenia is an independent predictor of morbidity and mortality in cirrhotic patient before and after liver transplantation. Beta-hydroxy-beta-methyl butyrate (HMB) is a leucine metabolite with pote...
Detailed Description
Protocol 1. Introduction: Sarcopenia, a condition of skeletal muscle mass depletion and reduction of muscle strength, is the most important aspect of malnutrition secondary to liver cirrhosis. Sa...
Eligibility Criteria
Inclusion
- 1\. Liver transplantation
Exclusion
- 1\. Multiple organ transplantation
- 2\. Low compliance
Key Trial Info
Start Date :
September 25 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 15 2018
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT03234920
Start Date
September 25 2015
End Date
September 15 2018
Last Update
March 11 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gastroenterology Department, Sapienza University of Rome
Rome, Italy, 00100